Context Therapeutics Inc (NASDAQ:CNTX) — Market Cap & Net Worth
Market Cap & Net Worth: Context Therapeutics Inc (CNTX)
Context Therapeutics Inc (NASDAQ:CNTX) has a market capitalization of $208.57 Million ($208.57 Million) as of May 5, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #16387 globally and #3705 in its home market, demonstrating a -2.16% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Context Therapeutics Inc's stock price $2.27 by its total outstanding shares 91879177 (91.88 Million). Analyse CNTX cash flow metrics to see how efficiently the company converts income to cash.
Context Therapeutics Inc Market Cap History: 2021 to 2026
Context Therapeutics Inc's market capitalization history from 2021 to 2026. Data shows change from $244.40 Million to $208.57 Million (-16.36% CAGR).
Index Memberships
Context Therapeutics Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.01% | #448 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #1600 of 3165 |
Weight: Context Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Context Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Context Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of CNTX by Market Capitalization
Companies near Context Therapeutics Inc in the global market cap rankings as of May 5, 2026.
Key companies related to Context Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Context Therapeutics Inc Historical Marketcap From 2021 to 2026
Between 2021 and today, Context Therapeutics Inc's market cap moved from $244.40 Million to $ 208.57 Million, with a yearly change of -16.36%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $208.57 Million | +54.42% |
| 2025 | $135.06 Million | +40.00% |
| 2024 | $96.47 Million | -7.08% |
| 2023 | $103.82 Million | +73.39% |
| 2022 | $59.88 Million | -75.50% |
| 2021 | $244.40 Million | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Context Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $208.57 Million USD |
| MoneyControl | $208.57 Million USD |
| MarketWatch | $208.57 Million USD |
| marketcap.company | $208.57 Million USD |
| Reuters | $208.57 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Context Therapeutics Inc
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the developm… Read more